CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
GUIDE.MRD focuses on improving cancer treatment outcomes by developing standardized diagnostic technologies, specifically liquid biopsy for detecting minimal residual disease. The project aims to enhance the selection of multimodal therapies through clinically validated circulating tumor DNA diagnostics.
Advancing personalized approaches in cancer therapy, aiding identification and adaptation of multi-modal treatment strategies for improved outcomes depends on clinical implementation of novel diagnostic technologies.
For most cancer types the risk-features used to select individuals for post-operative adjuvant multimodal therapy are suboptimal, where many patients are overtreated and others undertreated.
Liquid biopsy has opened a new diagnostic avenue to detect and monitor minimal residual dise…
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Denmark, Aarhus C
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
UNIVERSITAIR MEDISCH CENTRUM GRONINGEN
Netherlands, Groningen
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
FUNDACION SECTOR PUBLICO ESTATAL CENTRO NACIONAL INVESTIGACIONES ONCOLOGICAS CARLOS III
Spain, Madrid
Type: Research institute
Activity type: Research Organisations
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
